Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis

Samankaltaisia teoksia

• A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy
  Tekijä: Millns, Helen, et al.
  Julkaistu: (2015)
• Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
  Tekijä: Yu, Rosie Z., et al.
  Julkaistu: (2020)
• Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L(Rx) (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
  Tekijä: Coelho, Teresa, et al.
  Julkaistu: (2021)
• Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
  Tekijä: Viney, Nicholas J., et al.
  Julkaistu: (2020)
• Transthyretin familial amyloid polyneuropathy (TTR-FAP) in Mallorca: a comparison between late- and early-onset disease
  Tekijä: Raya-Cruz, Manuel, et al.
  Julkaistu: (2015)